Analytical Lifecycle Management (ALM) and Analytical Quality by Design (AQbD) for analytical procedure development of related substances in tenofovir alafenamide fumarate tablets

Jianhao Teng,Chunmei Zhu,Jinyuan Lyu,Linyu Pan,Meng Zhang,Fuli Zhang,Haoxiang Wu
DOI: https://doi.org/10.1016/j.jpba.2021.114417
IF: 3.571
2022-01-01
Journal of Pharmaceutical and Biomedical Analysis
Abstract:Analytical procedure development for quantifying 10 impurities in Tenofovir Alafenamide Fumarate (TAF) tablets was a challenge for analytical and formulation researchers. The aim of this paper was to develop a robust, regulatory-flexible, application-specific Ultra Performance Liquid Chromatography (UPLC) analytical procedure using the Analytical Lifecycle Management (ALM) and the Analytical Quality by Design (AQbD) for the estimation of the TAF tablets. In this work, the Analytical Target Profile (ATP) for the analytical procedure and the Critical Analytical Attributes (CAAs) were identified. Through the risk assessment studies, the high-risk analytical conditions were found, and they were screened and optimized by the Design of Experiment (DoE) to obtain the Design Space (DS) and identify the working point. The prediction intervals were used to examine the robustness of the analytical procedure. And the procedure performance qualification and the continued procedure performance verification were used to ensure routine application of analytical procedure. Finally, the 10 impurities were separated within 20 minutes by UPLC. The success of this study demonstrates that the usefulness of using ALM and AQbD for analytical procedure development and provides a reference for the analytical procedure development for other drugs.
pharmacology & pharmacy,chemistry, analytical
What problem does this paper attempt to address?